RBC
ALXN

Ronald Blue & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Ronald Blue & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-4,163
Closed -$651K – 308
2015
Q3 		$651K Buy
4,163
+811
+24% +$148K 0.03% 108
2015
Q2 		$606K Buy
3,352
+1,230
+58% +$212K 0.03% 137
2015
Q1 		$368K Sell
2,122
-378
-15% -$68.4K 0.02% 217
2014
Q4 		$463K Buy
2,500
+178
+8% +$33K 0.02% 173
2014
Q3 		$385K Buy
2,322
+270
+13% +$44.3K 0.03% 193
2014
Q2 		$321K Buy
2,052
+251
+14% +$39.6K 0.02% 219
2014
Q1 		$274K Sell
1,801
-136
-7% -$21.6K 0.02% 240
2013
Q4 		$257K Buy
+1,937
New +$232K 0.02% 241

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ronald Blue & Co's ALXN Position: Q4 2015 in Review

Ronald Blue & Co sold out of Alexion Pharmaceuticals (ALXN) in Q4 2015, closing a stake of 4,163 shares — an estimated $651K sold.

Ronald Blue & Co first reported a position in ALXN in Q4 2013 and held it in 8 quarters. The position peaked at $651K in Q3 2015. 549 funds tracked by Wall St. Rank hold ALXN as of Q4 2015.

  • Ronald Blue & Co reported no remaining Alexion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Ronald Blue & Co sold 4,163 Alexion Pharmaceuticals shares in Q4 2015, an estimated $651K.
  • Ronald Blue & Co first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 8 quarters.
  • Ronald Blue & Co's Alexion Pharmaceuticals position peaked at $651K in Q3 2015.
  • 549 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2015.

Based on Ronald Blue & Co's 13F filing for Q4 2015, filed 11 Feb 2016.